Literature DB >> 9869963

Combined radiofrequency ablation-cooling catheter for reversible cryothermal mapping and ablation.

F Shu1, V Lee, R Riley, M Pomeranz, W Su, D Melnick, M Homoud, C Foote, N A Estes, P J Wang.   

Abstract

Reversible cryothermal mapping of cardiac arrhythmias has been performed intraoperatively. However, a steerable cooling catheter for reversible mapping has not yet been developed. We therefore developed and tested a cooling system consisting of a -15 degrees C hypertonic saline reservoir and a 7F steerable catheter also capable of radiofrequency (RF) ablation. Using excised ovine hearts placed in a 37 degrees C circulating saline bath, we measured the temperatures at depths of 0 mm, 1 mm, and 2 mm. The temperature after 90 seconds of cooling was 16.5 +/- 2.1 degrees C at 0 mm compared to 23.9 +/- 4.1 degrees C at 1 mm and 31.1 +/- 3.9 degrees C at 2 mm depth (p < 0.01). These data suggest that a 7F steerable combined RF ablation-cooling catheter may achieve temperatures suitable for mapping arrhythmias such as atrial tachycardias and right ventricular outflow tract tachycardias. Further enhancements to achieve lower temperatures at depth may be needed to reversibly map other arrhythmias such as left ventricular tachycardias.

Entities:  

Mesh:

Year:  1997        PMID: 9869963     DOI: 10.1023/a:1009707216149

Source DB:  PubMed          Journal:  J Interv Card Electrophysiol        ISSN: 1383-875X            Impact factor:   1.900


  31 in total

1.  Subthreshold atrial pacing in patients with a left-sided accessory pathway: an effective new method for terminating reciprocating tachycardia.

Authors:  E S Gang; T Peter; P C Nalos; M Meesmann; H S Karagueuzian; W J Mandel; D S Oseran; M R Myers
Journal:  J Am Coll Cardiol       Date:  1988-03       Impact factor: 24.094

2.  Inhibition of premature ventricular extrastimuli by subthreshold conditioning stimuli.

Authors:  B T Skale; M J Kallok; E N Prystowsky; R M Gill; D P Zipes
Journal:  J Am Coll Cardiol       Date:  1985-07       Impact factor: 24.094

3.  Ventricular cryosurgery: short-term effects on intramural electrophysiology.

Authors:  W L Holman; M Ikeshita; J M Douglas; P K Smith; G K Lofland; J L Cox
Journal:  Ann Thorac Surg       Date:  1983-04       Impact factor: 4.330

4.  Cryothermal mapping and cryoablation in the treatment of refractory cardiac arrhythmias.

Authors:  J Camm; D E Ward; R A Spurrell; G M Rees
Journal:  Circulation       Date:  1980-07       Impact factor: 29.690

5.  Surgical treatment of ventricular tachycardia. Regional cryoablation guided by computerized epicardial and endocardial mapping.

Authors:  P L Pagé; R Cardinal; M Shenasa; W Kaltenbrunner; R Cossette; R Nadeau
Journal:  Circulation       Date:  1989-09       Impact factor: 29.690

6.  Cryothermal mapping of recurrent ventricular tachycardia in man.

Authors:  J D Gallagher; A J Del Rossi; J Fernandez; V Maranhao; M D Strong; M White; L J Gessman
Journal:  Circulation       Date:  1985-04       Impact factor: 29.690

7.  Cryosurgical ablation of the A-V node-His bundle: a new method for producing A-V block.

Authors:  L Harrison; J J Gallagher; J Kasell; R H Anderson; E Mikat; D B Hackel; A G Wallace
Journal:  Circulation       Date:  1977-03       Impact factor: 29.690

8.  Termination of sustained ventricular tachycardia by ultrarapid subthreshold stimulation in humans.

Authors:  M Shenasa; R Cardinal; T Kus; P Savard; M Fromer; P Pagé
Journal:  Circulation       Date:  1988-11       Impact factor: 29.690

9.  Dissociation of the site of origin from the site of cryo-termination of ventricular tachycardia.

Authors:  L J Gessman; T Endo; J Egan; J D Gallagher; R Hastie; P R Maroko
Journal:  Pacing Clin Electrophysiol       Date:  1983-11       Impact factor: 1.976

10.  A prospective randomized comparison of direct current and radiofrequency ablation of the atrioventricular junction.

Authors:  F Morady; H Calkins; J J Langberg; W F Armstrong; M de Buitleir; R el-Atassi; S J Kalbfleisch
Journal:  J Am Coll Cardiol       Date:  1993-01       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.